The Inflammatory Process and the Medical Imaging in Patients With an Inflammatory Disease of the Central Nervous System. (USPIO-CIS)
Early Neuroinflammatory Changes as a Prognostic Marker in Clinically Isolated Syndromes Patients.
Sponsor: Bayer
Terminated
terminated ( Halted prematurely,expiration of investigationnal product)
Other terminated trials from Bayer
Other Inflammatory Disease trials with similar outcome
Listed as NCT01567553, this observational or N/A phase trial focuses on Inflammatory Disease and Multiple Sclerosis (MS) and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Terminated NA
First recorded
Apr 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Rennes University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .